CIPLA CINACALCET cinacalcet (as hydrochloride) 60 mg tablet bottle

Country: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

cinacalcet hydrochloride, Quantity: 66.128 mg (Equivalent: cinacalcet, Qty 60 mg)

Disponibbli minn:

Cipla Australia Pty Ltd

Għamla farmaċewtika:

Tablet, film coated

Kompożizzjoni:

Excipient Ingredients: microcrystalline cellulose; pregelatinised starch; crospovidone; povidone; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

28's

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

Cipla Cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism (HPT) in patients with end stage renal disease, receiving dialysis (see section 5.1 Pharmacodynamic properties, Clinical trials). Cipla Cinacalcet should be used as adjunctive therapy.,Cipla Cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma.,Cipla Cinacalcet may be used to treat the biochemical manifestations of primary HPT in patients for whom parathyroidectomy is not a treatment option.

Sommarju tal-prodott:

Visual Identification: Light green coloured, oval shaped, biconvex film-coated tablets, debossed with "CL" on one side and "411" on other side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

L-istatus ta 'awtorizzazzjoni:

Registered

Data ta 'l-awtorizzazzjoni:

2023-02-07